Absence of BiP Co-chaperone DNAJC3 Causes Diabetes Mellitus and Multisystemic Neurodegeneration  by Synofzik, Matthis et al.
REPORT
Absence of BiP Co-chaperone DNAJC3 Causes
Diabetes Mellitus and Multisystemic Neurodegeneration
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Diabetes mellitus and neurodegeneration are common diseases for which shared genetic factors are still only partly known. Here, we
show that loss of the BiP (immunoglobulin heavy-chain binding protein) co-chaperone DNAJC3 leads to diabetes mellitus and wide-
spread neurodegeneration. We investigated three siblings with juvenile-onset diabetes and central and peripheral neurodegeneration,
including ataxia, upper-motor-neuron damage, peripheral neuropathy, hearing loss, and cerebral atrophy. Exome sequencing identified
a homozygous stopmutation inDNAJC3. Screening of a diabetes database with 226,194 individuals yielded eight phenotypically similar
individuals and one family carrying a homozygousDNAJC3 deletion. DNAJC3was absent in fibroblasts from all affected subjects in both
families. To delineate the phenotypic and mutational spectrum and the genetic variability of DNAJC3, we analyzed 8,603 exomes,
including 506 from families affected by diabetes, ataxia, upper-motor-neuron damage, peripheral neuropathy, or hearing loss. This anal-
ysis revealed only one further loss-of-function allele in DNAJC3 and no further associations in subjects with only a subset of the features
of the main phenotype. Our findings demonstrate that loss-of-function DNAJC3 mutations lead to a monogenic, recessive form of
diabetes mellitus in humans. Moreover, they present a common denominator for diabetes and widespread neurodegeneration. This
complements findings from mice in which knockout of Dnajc3 leads to diabetes and modifies disease in a neurodegenerative model
of Marinesco-Sjo¨gren syndrome.Nonautoimmune diabetes mellitus and neurodegenera-
tion are common disorders for which shared genetic
factors are still only partly known. Monogenic forms of
diabetes include neonatal diabetes (MIM 606176) and
maturity-onset diabetes of the young (MIM 606391),
both of which arise from mutations that primarily
reduce pancreatic b cell function.1 Although monogenic
forms account for only about 1%–2% of diabetes cases,
they provide unique insights into the underlying basic
disease mechanisms, such as endoplasmic reticulum
(ER) stress.2,3 Given that reduced mitigation of ER stress
due to genetic mutations has been shown to cause
both diabetes mellitus and multisystemic neurodegenera-
tion (e.g., in Wolfram syndrome 1 [MIM 222300]3,4), it
might present a shared mechanism linking diabetes with
neurodegeneration.
Mutations leading to loss of the ER protein DNAJC3—
which serves to attenuate late phases of ER stress5—have
been shown to lead to pancreatic b cell failure and diabetes
in mice.6 However, it is still unknown whether mutations
in DNAJC3 (MIM 601184; RefSeq accession number
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in DNAJC3 and the resulting absence of ER protein
DNAJC3 lead to diabetes mellitus and multisystemic
neurodegeneration.
Whole-exome sequencing (WES) was performed in two
affected individuals (61691 and 61695, who are subjects
II.2 and II.4, respectively, in family 1 in Figure 1A) of a
consanguineous Turkish family affected by juvenile-onset
diabetes and central and peripheral neurodegeneration,
including early-onset ataxia, upper-motor-neuron damage,
demyelinating peripheral neuropathy, neuronal hearing
loss, and cerebral atrophy. This procedure and all following
procedures reported in this manuscript were approved by
the institutional review board of the University of Tu¨bin-
gen in Germany (reference number 598/20118O1), and
proper informed consent was obtained from all subjects.
After in-solution capture of exonic sequences (SureSelect
Human All Exon 50 Mb Kit, Agilent Technologies), both
samples were sequenced to an average of 1263 and 1733
coverage on the Illumina platform (Genome Analyzer II3
System). For sequencing statistics, see Table S1 (available
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Figure 1. Pedigrees and DNJAC3 Mutations of the Index Families
(A) Pedigrees of the index families and segregation of the mutations identified in DNAJC3. Family 1 includes one unaffected and three
affected children of unrelated parents, and family 2 has two affected children of first-degree consanguineous parents. The identified
DNAJC3 variants segregated with the disease in all affected members of the two families, and testing of parents demonstrated that their
respective mutations are located in trans. Abbreviations are as follows: mut, mutation; and þ, wild-type.
(B) Representation of identified DNAJC3 mutations. A schematic of the exon-intron arrangement of DNAJC3 (RefSeq NM_ 006260.4)
includes the positions of the stop mutation identified in family 1 (top) and the deletion identified in family 2 (bottom). The electrophe-
rogram of the deletion breakpoint was analyzed with primers F1 and R1. Coding regions are indicated as blue boxes.0.5.8) for read alignment to the human reference assembly
(UCSC Genome Browser hg19) and SAMtools (version
0.1.7) for detection of single-nucleotide variants and small
insertions and deletions. Given the rare combination of
juvenile-onset diabetes and early-onset neurodegenera-
tion, we assumed the causative mutations to be rare and
to alter the protein sequence. We therefore excluded vari-
ants present in 4,517 exomes of control individuals with
unrelated phenotypes and searched for nonsynonymous
variants and splice-site mutations (Table 1). Given the
autosomal-recessive pattern of inheritance, we filtered
for genes harboring potential compound-heterozygous
or homozygous rare variants that were predicted to be
damaging by in silico prediction software tools (SIFT and
PolyPhen-2). This approach left only one gene with muta-
tions shared by both affected individuals: DNAJC3 (Table
1). The homozygous DNAJC3 mutation c.580C>T is pre-
dicted to cause premature truncation (p.Arg194*) of more690 The American Journal of Human Genetics 95, 689–697, Decembthan 60% of the protein sequence (Figure 1B). Sanger
sequencing of additional family members showed that all
three affected siblings harbor the c.580C>T mutation in
a homozygous state, whereas the healthy sister (subject
II.1 in Figure 1A) has two wild-type alleles. Testing of par-
ents demonstrated that bothmutations are located in trans
(for electropherograms of the Sanger sequences of all pedi-
gree members, see Figure S1).
To confirm the significance of DNAJC3mutations in the
pathogenesis of diabetes-neurodegeneration syndromes,
we screened the German multicenter DPV (Diabetes Pa-
tienten Verlaufsdokumentation) registry, which contains
226,194 pediatric and adult individuals with diabetes
from 354 treatment centers. According to the key pheno-
typic characteristics of the affected members of index
family 1 (for a detailed description, see Table 2 and the
paragraph below), we used the following clinical screening
criteria: (1) diabetes onset at age 10–20 years, (2) absence ofer 4, 2014
Table 1. Variants Identified by Exome Sequencing in Affected
Individuals of Index Family 1
II.2 (61691) II.4 (61695) Present in Both
NSVs not present
in 4,517 control
individuals
216 238 119
At least two
NSVs per gene
11 14 5 (PDCD11,
DNAJC3, KIF23,
CPT1C, MAGEC1)
Two NSVs
predicted to be
damaging and
present in both
2 1 1 (DNAJC3)
At least two loss-
of-function alleles
1 (DNAJC3) 1 (DNAJC3) 1 (DNAJC3)
Nonsynonymous variants (NSVs) include missense, nonsense, stop-loss, and
splice-site mutations and insertions and deletions. Variants were predicted to
be damaging by at least one out of three software predictions (SIFT, Poly-
Phen-2, and MutationTaster).b cell antibodies, (3) body mass index (BMI) below the
median for age and gender, and (4) ataxia and/or hearing
impairment. This filter left 35 individuals (31 with hearing
impairment, two with ataxia, and two with hearing im-
pairment and ataxia). Because the registry does not
collect biomaterials, these 35 individuals were approached
through their treatment centers (29 centers in total) by
their local clinicians and were asked to provide a DNA sam-
ple for DNAJC3 analysis. DNA could be obtained from
eight index subjects. Conventional Sanger sequencing
(oligonucleotide sequences are available upon request)
revealed no mutation in seven of eight subjects. In one
of the two index subjects with hearing impairment and
ataxia, we failed to amplify exons 612 by PCR, whereas
PCR amplification delivered the expected DNA fragments
for exons 1–5 in the same sample and for exons 1–12 in
control samples, suggesting a potential deletion affecting
exons 6–12. Breakpoints of the expected deletion were
characterized by PCR and a primer-walking approach and
were confirmed by Sanger sequencing (Figure 1B). This
72 kb homozygous deletion was also identified in the
affected sibling (subject II.2 of family 2, Figure 1A) and
was heterozygous in the parents (subjects I.1 and I.2 of
family 2, Figure 1A).
To delineate the phenotypic and mutational spectrum
and the genetic variability of DNAJC3, we screened a total
of 8,603 exomes (4,303 from the Hussman Institute for
Human Genomics [Miami] via the Genomes Management
Application7 and 4,300 from the Institute of Human
Genetics [Munich]) for rareDNAJC3 variants. Among these
8,603 exomes, 506 unrelated index subjects with a family
history consistent with recessive disease presented with
at least one of the main phenotypic features of the
DNAJC3 phenotypic cluster: diabetes (n ¼ 30), early-
onset ataxia (age of onset < 30 years; n ¼ 69), hereditary
spastic paraplegia (n ¼ 161), Charcot-Marie-Tooth disease
type 2 (n ¼ 153), or deafness (n ¼ 93). In a first step,
we screened all 8,603 exomes for potential homozygousThe Americanor compound-heterozygous variants in DNAJC3 by using
the following filter criteria: low frequency in public data-
bases (minor allele frequency < 1% in the NHLBI Exome
Sequencing Project Exome Variant Server [ESP6500])
and genotype quality > 35. We identified two families
affected by homozygous DNAJC3 missense mutations
(family 1: c.207T>A [p.Asp69Glu]; family 2: c.1060G>C
[p.Glu354Gln]) and one family harboring compound-
heterozygous DNAJC3 missense mutations (c.641C>T
[p.Ala214Val] and c.1037G>A [p.Arg346Gln]), but none
of these mutations was considered to be disease causing
(for details, see Table S2 and Figure S2). Apart from our in-
dex family 1, we did not identify any other family carrying
two predicted loss-of-function variants in DNAJC3. Taken
together, these findings suggest the following notion:
although biallelic loss-of-function mutations in DNAJC3
cause diabetes and a multisystemic combination of ataxia,
peripheral neuropathy, upper-motor-neuron disease, and
hypacusis, they do not seem to be associated with only
one of these features or a small subset of them.
Next, we analyzed the overall occurrence ofDNAJC3 var-
iants to determine the genetic variability of DNAJC3 (same
filters as above, but no inheritance filter). In 8,603 exomes,
we identified 56 alleles with rare DNAJC3 variants, consist-
ing of 41 unique variants (one stop [c.580C>T from index
family 1], one frameshift, and 39 missense; see Table S3).
This observation demonstrates that truncating variants
in DNAJC3 are a very rare event (2 out of 17,206 alleles)
and that genetic variability of DNAJC3 is low overall (56
events out of 17,206 alleles). This notion receives further
independent support from the Residual Variation Intoler-
ance Score (RVIS), which is based on the 6,500 exomes
from NHLBI ESP6500.8 This score provides a measure of
the departure from the (genome-wide) average number of
common functional mutations found in genes with a
similar amount of mutational burden (RVIS ¼ 0 when
the gene has an average number of common functional
variants given its total mutational burden, RVIS <
0 when the gene has less common functional variation
than predicted, and RVIS > 0 when the gene has more).8
DNAJC3 yields a RVIS of 0.47, ranking it among the
23% most intolerant of human genes.8 Genes such as
DNAJC3, which are more intolerant of functional genetic
variation, have been shown to be significantly more likely
than other genes to harbor mutations that cause Mende-
lian diseases.8
DNAJC3 acts as co-chaperone of BiP (immunoglobulin
heavy-chain binding protein), a major ER-localized mem-
ber of the HSP70 family of molecular chaperones, which
reversibly bind to contiguous segments of hydrophobic
amino acids exposed in unfolded lumenal proteins
to impede aggregation and promote adequate folding.9
DNAJC3 is located in virtually all tissues in mice and hu-
mans and has especially high levels in the pancreas and
liver.10 In mice, loss of DNAJC3 leads to hyperglycemia
and glucosuria associated with increasing apoptosis of
pancreatic b cells and reduced insulin levels.6 To validateJournal of Human Genetics 95, 689–697, December 4, 2014 691
Table 2. Characteristics of Subjects with Homozygous Loss-of-Function DNAJC3 Mutations and Healthy Sister 54829
Index Family 1 Index Family 2
II.2 (61691) II.3 (61693) II.4 (61695) II.1 (54829) II.1 (66050) II.2 (66051)
DNAJC3 variant c.580C>T
(p.Arg194*)
c.580C>T
(p.Arg194*)
c.580C>T
(p.Arg194*)
NA deletion of exons
6–12 (p.?)
deletion of exons
6–12 (p.?)
Age at examination 39 years 34 years 20 years 41 years 20 years 14 years
Sex male female male female female female
Below-average body
height (percentilea)
þ, 152 cm (<3%) þ, 145 cm (<3%) þ, 156 cm (25%) þ, 155 cm (25%) þ, 136 cm (<3%) þ, 143 cm (3%)
Below-average body
weight (percentilea)
þ, 45 kg (<3%) þ, 38 kg (<3%) þ, 49 kg (10%) , 65 kg
(75%–90%)
þ, 39 kg (<3%) þ, 39 kg (<3%)
Reduced BMI
(percentile)
þ, 19.5
(5%–10%)
þ, 18.1 (<3%) þ, 20.1
(25%–50%)
, 27.1
(75%–90%)
þ, 21.1
(25%–50%)
þ, 19.4
(25%–50%)
Age at onset of
diabetes
18 years 18 years 15 years no diabetes 14 years 11 years
Diabetes insulin
treatment
þ þ þ  þ þ
HbA1c
(ref: 4.3%–6.1%)
7.4% 6.9% 12.1% NA 7.5% 7.9%
IA-2 antibodies
(ref: <0.9 U/ml)
0.1 U/ml 0.2 U/ml 0.2 U/ml NA 0.2 U/ml 0.4 U/ml
GAD2 antibodies
(ref: <0.9 U/ml)
0.1 U/ml 0.4 U/ml 2.1 U/ml NA 0.1 U/ml 0.1 U/ml
Age at onset of
hypacusis
6 years 27 years 14 years NA 2 years NA
Age at onset of gait
disturbance
6 years 34 years 19 years NA 2 years 11 years
Afferent ataxia þ þ þ  þ þ
Lower-limb areflexia  þ þ  þ 
Babinski sign þ/þ / /  þ 
MMSE score 27/30 27/30 25/30 30/30 ND ND
Backward calculation
(MMSE subscore)
2/5 2/5 0/5 5/5 ND ND
SARA score 18.5/40 4/40 4/40 0/40 35/40 4/40
MEP not evoked to all
limbs
not evoked to all
limbs
not evoked to all
limbs
ND ND ND
Tibial SEP not evoked not evoked not evoked ND ND ND
Sensory NCSb
Sural
(ref: >3.8 mV, >39 m/s)
4.3 mV,
29 m/s (YY)
no SNAP (YY) 0.5 mV (YY),
25 m/s (YY)
ND no SNAP (YY) no SNAP (YY)
Radial
(ref: >16 mV, >50 m/s)
10.9 mV (Y),
37 m/s (YY)
8.5 mV (Y),
32 m/s (YY)
no SNAP (YY) ND no SNAP (YY) ND
Motor NCSc
Tibial
(ref: >5 mV, >40 m/s)
12.8 mV,
27 m/s (YY)
13.6 mV,
23 m/s (YY)
6.6 mV,
23 m/s (YY)
ND 0.2 mV (YY),
16 m/s (YY)
9.5 mV,
20 m/s (YY)
Ulnar
(ref: >5 mV, >50 m/s)
10.5 mV,
33 m/s (YY)
14.9 mV,
32 m/s (YY)
13.4 mV,
29 m/s (YY)
ND 11.6 mV,
24 m/s (YY)
ND
Abbreviations are as follows: BMI, body mass index; MEP, motor evoked potential; MMSE, Mini-Mental State Examination16; NA, not applicable; NCS, nerve con-
duction study; ND, not done; ref, reference value; SARA, Scale for the Assessment and Rating of Ataxia; SEP, sensory evoked potential; SNAP, sensory nerve action
potential; Y, reduced value; and YY, severely reduced value.
aPercentiles of body weight and body height were taken from reference values for German-born Turkish children and adults (18 years).
bSNAPs are given in mV, and sensory nerve conduction velocities are given in m/s.
cCompound muscle action potentials are given in mV, and motor nerve conduction velocities are given in m/s.
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Figure 2. Immunoblot of DNAJC3
The immunoblot shows the absence of DNAJC3 in all affected sub-
jects (with blue IDs) of both families, whereas the two heterozy-
gous parents (with black IDs) of the siblings in family 2 showed
normal protein levels. Immunoblot analysis was performed as
described previously.11 DNAJC3 antibody (rabbit, Cell Signaling
Technology) was used at 1:1,000. b-actin antibody (Sigma-Aldrich)
was used at 1:10,000.the predicted loss-of-function character of the identified
mutations in both families, we analyzed DNAJC3 in fibro-
blasts by immunoblotting. Neither full-length nor trun-
cated DNAJC3 was detected in the affected individuals,
whereas the two heterozygous parents showed normal
protein levels (Figure 2). Given the well-established func-
tion of DNAJC3 in the downregulation of ER-associated
proteins involved in the initial ER stress response, as
well as the histopathological changes observed in some
DNAJC3-deficient cell types,6 we investigated the ER
morphology in fibroblasts from our individuals with
DNAJC3 loss of function. No changes in ER morphology
were observed by electron microscopy (Figure S3). This is
in line with the previous finding that histological changes
associated with the absence of DNAJC3 can be found only
in some tissues (e.g., pancreatic islets), but not in others
(e.g., pancreatic acini or other pancreatic parenchyma).6
We analyzed protein trafficking through the secretory
pathway in cell lines from subjects with homozygous
DNJAC3 mutations and healthy control individuals by
monitoring the secretion of Gaussia princeps luciferase
into the culture medium.12 Induction of ER stress by thap-
sigargin (an inhibitor of the ER Ca2þ ATPase) or tunicamy-
cin or glucose deprivation (both of which interfere with
N-linked protein glycosylation) resulted in impaired secre-
tion in mutant and control cells. No significant differences
were noted through induction or recovery from ER stress
(Figure S4), indicating intact protein secretion in fibro-The Americanblasts. In addition, we analyzed subjects’ fibroblasts for a
difference in ER calcium leakage. It has been shown for
HeLa cells that a loss of BiP function leads to increased
ER calcium leakage, as does replacement of BiP by an
altered BiP variant, which cannot productively interact
with its HSP40 co-chaperones.13 However, no increased
ER calcium leakage was observed (Figure S5). Taken
together, these experiments again point to the fact that fi-
broblasts might not be the most appropriate tissue for
testing for DNAJC3-related ER stress and calcium leakage,
most likely because of their low secretory activity and/or
the compensatory mechanisms that are active in the
affected subjects. However, no other tissue (e.g., pancreatic
b cells or neurons) was available for testing.
We aggregated clinical, electrophysiological, and imag-
ing data from all five affected subjects belonging to the
two index families affected by DNAJC3 loss-of-function
mutations. Before identification of the DNAJC3 muta-
tions, the phenotype in family 1 was clinically classified
as a mitochondriopathy, and the phenotype in family 2
was classified as an atypical Shwachman-Bodian-Dia-
mond syndrome (MIM 260400). All five affected subjects
presented with young-onset diabetes melllitus diagnosed
between 10 and 20 years of age, showed increased HbA1c
levels (6.9%–12.1%), and received insulin treatment
(Table 2). IA-2 antibodies were absent in all five subjects,
and GAD2 antibodies were present in four of five subjects
(Table 2). C-peptides—which reflect the degree of residual
pancreatic b cell function—were assessed in fasting serum
and upon response to standardized intravenous applica-
tion with 1 mg of glucagon13 (Table S4). Residual endog-
enous insulin secretion was present in all subjects, and
secretion could be stimulated by glucagon (both are char-
acteristic of most monogenic forms of diabetes14). How-
ever, all subjects showed an at least relative deficit in
insulin secretion, given that fasting C-peptide levels
were low in absolute levels and/or in relation to the
actual glucose levels and HbA1c levels (Table S4). Fasting
C-peptide levels were in the same low range as reported
for other monogenic forms of diabetes (between 100
and 700 pmol/l14). The presence of residual endogenous
insulin stimulation by glucagon in subjects with >3 years
of diabetes history and the absence of autoimmune
antibodies clearly argues against a diabetes mellitus
type 1.15
All subjects exhibited multisystemic central and periph-
eral neurodegeneration. This included early-onset ataxia
of combined cerebellar and afferent origin (age of onset
¼ 2–34 years) and sensorimotor peripheral neuropathy
predominantly of the demyelinating type (Table 2), which
was observed even in the subject with the most recent dis-
ease onset of 6 months earlier (subject II.2 in family 2).
Four of five (80%) individuals developed early-onset senso-
rineural hearing loss (range of onset¼ 2–27 years), and two
of five (40%) showed pyramidal tract signs (Table 2).
Cognitive screening by the Mini-Mental State Examina-
tion16 in family 1 revealed an isolated cognitive deficit inJournal of Human Genetics 95, 689–697, December 4, 2014 693
Figure 3. MRI and Body Stature of Subjects with DNAJC3 Loss-of-Function Mutations
MRI of subjects withDNAJC3 loss-of-functionmutations (A–G) and short stature and low BMI in an exemplary affected subject (H). MRI
of index subjects II.2 (61691) from family 1 (A–D) and II.1 (66050) from family 2 (E–G) revealed generalized supra- and infratentorial
atrophy pronounced in the cervical and thoracic cord (arrowheads; A, D, and E), cerebellar vermis (arrows; A and E), and crus cerebri
and midbrain (arrows; C and F) in both subjects and in the pre- and postcentral gyrus in subject II.2 from family 1 (arrows; B). Subject
II.1 (66050) from family 2 also showed several small T2 hyperintense lesions without contrast enhancement bilaterally in the frontopar-
ietal and periventricular regions (arrows; G). In index family 1, affected subject II.3 (61693; H, right) has a lower BMI and shorter stature
than her unaffected sister, II.1 (54829; H, left).backward calculation of serial sevens, suggesting partial
cerebrocortical dysfunction. All five affected subjects
from the two index families had a below-average body
weight (four were below the third percentile, and one
was at the tenth percentile) and a below-normal BMI
(one was below the third percentile, one was below the
tenth percentile, and three were below the 50th percentile),
whereas both body weight and BMI were above average in
the healthy sister (II.1) from family 1 (each were between
the 75th and 90th percentiles; Table 2; Figure 3H). All five
affected subjects also showed a remarkably short body stat-
ure (four were below the third percentile, and one was at
the 25th percentile; for an example, see Figure 3H), suggest-
ing that it is highly likely that this is also part of the pheno-
type associated withDNAJC3mutations. However, because
body stature was also below average in the healthy sister
(II.1) from family 1, future studies are warranted to confirm
this feature. MRI available for index subjects II.2 (61691) of
family 1 and II.1 (66050) of family 2 revealed generalized
supra- and infratentorial atrophy pronounced in the cervi-
cal cord, cerebellar vermis, cerebellar hemispheres, and
midbrain in both subjects and in the pre- and postcentral
gyrus, crus cerebri, pons, and medulla in subject II.2
(Figure 3). Subject II.1 (66050) of family 2 also showed
several small T2 hyperintense lesions without contrast
enhancement bilaterally in frontoparietal and periventric-
ular regions (Figure 3G).694 The American Journal of Human Genetics 95, 689–697, DecembDnajc3 knockout causes gradual onset of hyperglycemia
and glucosuria associated with increasing apoptosis of
pancreatic b cells in mice, thus mimicking disease
processes in type 1 and late-stage type 2 diabetes.6 Our
findings demonstrate that—analogous to the mouse
model—homozygous DNAJC3 loss-of-function mutations
cause young-onset diabetes in humans. Moreover, like
Dnajc3-knockout mice,6 humans with DNAJC3 loss-of-
function mutations also show a lower body weight, prob-
ably because of less body fat.6
Our findings also reveal that the absence of DNAJC3 is
associated not only with diabetes mellitus but also with
widespread neurodegeneration (which was not studied in
detail in the Dnajc3-knockout mice6). It has already been
shown for mutations in other genes encoding ER-localized
BiP co-chaperones that they can lead tomultisystemic neu-
rodegeneration. For example, mutations in SIL1 lead to
Marinesco-Sjo¨gren syndrome (MSS [MIM 248800]), a mul-
tisystemic syndrome including early-onset ataxia, cogni-
tive deficits, short stature, and pyramidal tract signs,17–19
thus mirroring main features of the phenotype associated
with DNAJC3 mutations. Both genes not only are linked
phenotypically but also interact on a molecular level.
Within the regulation of the BiP ATP-ADP cycle, DNAJC3
and SIL1 have opposing functions—loss of DNAJC3 has
been shown to ameliorate cerebellar Purkinje cell death
and ataxia in SIL1/ mice.20er 4, 2014
Figure 4. Role of DNAJC3 in the UPR and Its Interaction with Other Proteins Associated with Human Disease
DNAJC3 (brown ovals) belongs to the DNAJ proteins localized in the lumen of the ER. It directly binds and recruits unfolded proteins
(twisted black lines) in order to hand them over to the molecular chaperone BiP (green boxes). BiP is a central target of UPR signaling.
Inter alia, it interacts with SIL1 (red circles), a nucleotide exchange factor, to restore adequate folding of misfolded proteins. An over-
whelming load of misfolded proteins requires more of the available BiP to bind to the exposed hydrophobic regions of these misfolded
proteins. To meet this requirement, BiP dissociates from ER-transmembrane sensors, such as PERK (blue circles). The oligomerization of
PERK and the consequent autophosphorylation of the free luminal domain lead to the activation of PERK. The activated cytosolic
domain of PERK causes translational attenuation by directly phosphorylating the a subunit of the regulating initiator of themRNA trans-
lation machinery, eIF-2a (blue boxes). This attenuation of translation further reduces the stress induced by misfolded proteins. Several
mutations in genes encoding proteins of these UPR pathways are well established in human diseases. Mutations in EIFKA3, encoding
PERK, cause WRS, which is characterized by young-onset nonautoimmune insulin-requiring diabetes, skeletal dysplasia, and short stat-
ure and thereby resembles several hallmarks of the DNAJC3-deficiency phenotype. Defects in SIL1 cause MSS.18,19 Clinical manifesta-
tions of MSS include early-onset cerebellar ataxia and short stature, thus also mirroring hallmarks of DNAJC3 disease.Dysfunctions in the regulation of ER stress might thus
serve as a common pathway linking diabetes mellitus
and neurodegeneration. It has already been shown for mu-
tations in other genes involved in the regulation of ER
stress that they can lead to monogenic diabetes mellitus
and multisystemic neurodegeneration, e.g., for mutations
in the gene encoding ER-localized transmembrane protein
WFS1.3,4 WFS1 neurodegeneration includes early-onset
ataxia, sensorineural hearing loss, and cognitive deficits
(Wolfram syndrome 121,22), thus mirroring several of the
systems also affected by DNAJC3-associated neurodegener-
ation. Likewise, mutations are well established for otherThe Americangenes encoding proteins directly involved in signaling
of the endoplasmic unfolded protein response (UPR),
which acts up- and downstream of DNAJC3 (Figure 4).
For example, mutations in EIFKA3 (MIM 604032), coding
for the UPR signaling protein PERK (PRKR-like endo-
plasmic reticulum kinase; Figure 4), causeWolcott-Rallison
syndrome (WRS [MIM 226980]), characterized by young-
onset nonautoimmune insulin-requiring diabetes, skeletal
dysplasia, and short body stature and thereby resembling
several hallmarks of the DNAJC3-deficiency phenotype.
Likewise, defects in SIL1 (MIM 608005), which encodes a
protein upstream of DNAJC3 in the UPR (Figure 4), causeJournal of Human Genetics 95, 689–697, December 4, 2014 695
MSS.17–19 Clinical manifestations of MSS include early-
onset ataxia and short stature, thus again mirroring several
features of the DNAJC3-deficiency phenotype.
In summary, we have identified DNAJC3 mutations as a
cause ofmonogenic juvenile-onset diabetes combinedwith
early-onset multisystemic neurodegeneration. DNAJC3
plays a crucial role in ER protein folding and the UPR, thus
adding evidence that dysfunctions in regulation of ER stress
might serve as a commonpathway linkingdiabetesmellitus
and neurodegeneration. DNAJC3might be linked to neuro-
degeneration in other ER-stress-induced and UPR diseases
(e.g., Wolfram syndrome 1, WRS, and MSS) not only on a
phenotypic level but also on a molecular level.Supplemental Data
Supplemental Data include five figures and four tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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